USA-based firm ArQule's loss was marginally deeper for the three months ending September 30, 2008, compared to the same period of the year before, on flat sales and dropping interest income.
Revenue was $2.7 million during both periods, all from R&D activities, expenses for which were 14% lower at $10.8 million. Interest income, however, fell to $557,000 versus $2.0 million.
The firm's net loss worsened by 2% to $11.3 million, though loss per share remained flat at $0.26. The company's cash, cash equivalents and short-term marketable securities have nearly halved since December 31, 2007, falling to just $74.7 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze